Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma

Annals of Hepatology

Volumn 11, Issue 6, 2012, Pages 899-906

  Baldissera, Vanessa Dido ^a   de Mattos, Angelo Alves ^a   Coral, Gabriela Perdomo ^a   de Araujo, Fernanda Branco ^a   Marroni, Cláudio Augusto ^a   Brandão, Ajácio Bandeira de Mello ^a   Fontes, Paulo Roberto Ott ^a   Cerski, Carlos Thadeu Schmidt ^b   Hartmann, Antonio Atalibio ^a   Filho, Nélson Alexandre Kretzmann ^c  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Liver tumors; Multidrug resistance gene; P glycoprotein; Single nucleotide polymorphism

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

EID: 84869839802     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31416-4     Document Type: Article

References (31)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epide-miology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Roberts LR. Sorafenib in liver cancer-Just the beginning. N Engl J Med 2008; 359: 420-2.
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
4. Bruix J, Sherman M. Management of hepatocellular carci-noma: An update. Hepatology 2011; 53: 1020-2.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatoce-llular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Brose MS, Smyrk T, Weber B, Lynch HT. Genetic predisposi-tion to cancer-cancer etiology. In: Bast RC Jr, Kufe DW, Po-llock RE, Weichselbaum RR, Holland JF, Frei E (eds.). Cancer Medicine. Ontario, Canada: BC Becker; 2000, p. 168-84.
7. The Human Genome. Disponível em: http://genome.wellcome.ac.uk/ [Acesso em: 28 de Março de 2011].
8. Gottesman MM, Pastan I. Biochemistry of multidrug resis-tance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
9. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Can-cer 2002; 2: 48-58.
10. Huang JS, Zhang XJ, Xu X, Guan M, Zhou YL, Lü L, Zou HJ. Influence of MDR1 gene C3435T on peripheral white blood cell counts in workers exposed to benzene. Chi J Ind Hyg Oceup Dis 2011; 2: 20-3.
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmö-ller J, Johne A, Cascorbi I, et al. Functional polymorphisms of the human multidrug resistance gene: Multiple sequen-ce variations and correlation of one allele with P-glycopro-tein expression and activity in vivo. Proc Natl Acad Sci 2000; 97: 3473-8.
12. Leslie EM, Deeley RG, Cole SPC. Multidrug resistance pro-teins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-37.
13. Jamroziak K, Miynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, et al. Functional C3435T polymorphism of MDR1 gene: an impact on gene-tic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haemato 2004; 72: 314-21.
14. Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T=A gene polymor-phism is associated with high risk of lung cancer. Cancer 2006; 107: 2850-7.
15. Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV. The mechanism of action of multi-drug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001; 33: 481-91.
16. Avendano C, Menendez JC. Inhibitors of multidrug resis-tance to antitumor agents (MDR). Curr Med Chem 2002; 9: 159-93.
17. Fromm MF. Genetically determined differences in P-glyco-protein function: Implications for disease risk. Toxicology 2002; 182: 299-303.
18. Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB. P-glycoprotein expression is a marker for chemo the-rapy resistance and prognosis in advanced ovarian can-cer. Anticancer Res 2000; 20: 1061-7.
19. Alves MTS, Miiji LNO, Marinho LC, Toledo SRC, Patrício FRS, Garcia-Filho RJ, Petrilli AS, et al. Osteossarcomas hu-manos de alto grau: imunoexpressão de p53, erb-2 e P-gli-coproteína, e correlação com o parâmetro anaplasia. J Bras Patol Med Lab 2008; 44: 107-14.
20. Sjöholm MI, Hoffmann G, Lindgren S, Dillner J, Carlson J. Comparison of archival plasma and formalin-fixed para-ffin-embedded tissue for genotyping in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 251-5.
21. Silva M, Mattos AA, Fontes PR, Waechter FL, Pereira-Lima L. Evaluation of hepatic resection for hepatocellular carcinoma on cirrhotic livers. Arq Gastroenterol 2008; 45: 99-105.
22. Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Al-ves de Mattos A, Míguez C, et al. Etiology of hepatocellu-lar carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol 2010; 1: 63-9.
23. Huang CC, Wu MC, Xu GW, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84: 262-64.
24. Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007; 38: 539-44.
25. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 poly-morphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010: 12: 34-40.
26. Siegsmund M, Brinkmann U, Scháffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-54.
27. Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Fi-rouzi F, Aghazadeh R, Daryani NE, et al. The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int J Colorectal Dis 2007; 22: 999-1003.
28. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glyco-protein expression in human liver. Br J Clin Pharmacol 2005; 59: 365-70.
29. Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, et al. MDR1 gene polymorphisms and risk of recurrence in pa-tients with hepatocellular carcinoma after liver transplan-tation. J Surg Oncol 2007; 96: 62-8.
30. Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, Liang H, et al. Relevance of two genes in the multidrug resistance of he-patocellular carcinoma: in vivo and clinical studies. Tumori 2010; 96: 90-6.
31. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multi-drug resistance polypeptide 1 (MDR1, ABCB1) variant 3435>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.